Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy.

Ye Won Jeon Seung Taek Lim Hongki Gwak Seon Young Park Young Jin Suh

Published in: Journal of breast cancer (2020)

The use of pegfilgrastim during adjuvant TAC chemotherapy was significantly associated with a decrease in the incidence and risk of FN, hospital care costs, and risk of death compared to the use of adjuvant TAC without primary prophylaxis.

Keyphrases

early stage
locally advanced
healthcare
chemotherapy induced
low dose
palliative care
risk factors
high dose
cancer therapy
radiation therapy
quality improvement
electronic health record
health insurance
breast cancer risk